Buloxibutid
- Generic Name
- Buloxibutid
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H29N3O4S2
- CAS Number
- 477775-14-7
- Unique Ingredient Identifier
- RC2V4W0EYC
- Associated Conditions
- -
- Associated Therapies
- -
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People with Idiopathic Pulmonary Fibrosis.
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Vicore Pharma AB
- Target Recruit Count
- 270
- Registration Number
- NCT06588686
- Locations
- 🇬🇷
"Sotiria" Chest Diseases Hospital of Athens - Site 1, Athens, Greece
🇬🇷"Sotiria" Chest Diseases Hospital of Athens - Site 2, Athens, Greece
🇬🇷University General Hospital "Attikon", 2nd Pulmonary Department, Athens, Greece
Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Anna Stanhewicz, PhD
- Target Recruit Count
- 30
- Registration Number
- NCT06157580
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Anna Stanhewicz, PhD
- Target Recruit Count
- 30
- Registration Number
- NCT05937841
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Sex Differences in the Dilatory Response of Compound 21
Early Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Anna Stanhewicz, PhD
- Target Recruit Count
- 24
- Registration Number
- NCT05576155
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath